509 results about "Cholic acid" patented technology

The invention relates to the technical field of inorganic non-metallic materials, in particular to a quaternized cholic acid polyurethane modified polyvinyl chloride material, a preparation method and application. The quaternized cholic acid polyurethane polymer is based on a polyurethane elastomer developed by using cholic acid molecules with a rigid skeleton as a hard segment unit and flexible oligomeric ethylene glycol as a soft segment unit, hydroxyl on cholic acid polyurethane is quaternized to prepare cation modified cholic acid polyurethane, and the cation modified cholic acid polyurethane simulates amphiphilic characteristics of natural peptides. The quaternized cholic acid polyurethane is introduced into a polyvinyl chloride (PVC) matrix as an antibacterial agent, so that the growth of microorganisms such as bacteria and molds can be effectively inhibited, the antibacterial property is achieved, bacteria breeding on the inner surface of a pipeline is avoided, and the composite material is endowed with better biocompatibility and antibacterial property; meanwhile, the quaternized cholic acid polyurethane can effectively improve the strength and toughness of the PVC material; wide application prospects are realized.

The invention relates to application of 12-ketolithocholic acid in preparation of a medicine for preventing or treating acute ischemic intestinal injury. According to the application, 12-ketolithocholic acid (12-KLCA) is used for preventing or treating acute ischemic intestinal injury and is verified on a constructed classical intestinal ischemia reperfusion model, and a verification result shows that the 12-KLCA obviously improves intestinal histopathologic injury induced by intestinal ischemia reperfusion of a mouse, improves the survival rate of the mouse, and has a good application prospect in prevention or treatment of acute ischemic intestinal injury. The protein expression level of the apoptosis factor activated caspase-3 is reduced, the effect is obvious, safety and non-toxicity are achieved, and the side effect is small.

The invention discloses hawthorn leaf pectic polysaccharide with lipid-lowering activity and a preparation method and application thereof, and belongs to a preparation method of plant polysaccharide, the preparation method comprises the following steps: refluxing hawthorn leaves with ethanol, discarding monosaccharide and small molecule compounds, refluxing with hot water to extract medicinal materials, removing protein through an enzymolysis method and a Sevage reagent method, decolorizing with polyamide resin, and drying to obtain the hawthorn leaf pectic polysaccharide with lipid-lowering activity. The crude polysaccharide is separated through DEAE-52 column chromatography, and finally, the crude polysaccharide is further purified through Sephadex G-100, so that the uniform purified polysaccharide is obtained. Tests on pancreatic lipase inhibition, taurocholate binding capacity and glycocholate binding rate show that the compound has remarkable lipid-lowering activity and is expected to become a potential natural lipid-lowering preparation.

The invention relates to the field of biomedicine, particularly provides a copper-based nano-enzyme as well as a preparation method and application thereof, and aims to solve the problems that in the prior art, clinical treatment on primary sclerosing cholangitis (PSC) is difficult in diagnosis and lacks of effective treatment drugs. The copper-based nano-enzyme comprises a nano-enzyme carrier and a copper-based nano-enzyme, wherein the nano-enzyme carrier is a two-dimensional nanosheet formed by copper ions, gallic acid and ursodesoxycholic acid through coordinate bonds; the probe molecule is a cyanine dye molecule connected to the surface of the nano-enzyme carrier through a covalent bond; wherein the fluorescence intensity of the copper-based nano enzyme is enhanced after the action of the alkaline phosphatase. The three functions of alkaline phosphatase responsive diagnosis, nano-enzyme catalytic treatment and ursodesoxycholic acid hepatic targeting are innovatively and synergistically integrated into one nano platform, the treatment function can be executed while specific imaging diagnosis is performed on diseases, and a new strategy is provided for diagnosis and treatment of diseases such as PSC.

The present invention relates to antisense oligonucleotides (AONs) that can mediate RNA editing by binding to a target RNA nucleic acid molecule, preferably an RNA transcript molecule, in a cell and recruiting an endogenous deaminating enzyme in the cell to deaminate a target adenosine in the target RNA molecule to an inosine. The target RNA molecule is a transcript molecule form the SLC10A1 gene that encodes the Na+ / Taurocholate Co-transporting Polypeptide (NTCP), and the target adenosine is the adenosine in the GAC codon coding for aspartic acid (D) at position 24 of the NTCP protein. The deamination of the adenosine changes the amino acid to a glycine (G). The RNA editing of the adenosine will result in a loss-of-function of the NTCP protein, which will result in lowered uptake of bile acids from the portal circulation into the liver, thereby lowering the risk of suffering from disorders related to bile accumulation in the liver.

The invention belongs to the technical field of microorganisms, and particularly relates to bacillus cereus as well as a culture and application thereof. The preservation number of the bacillus cereus AK-LY1 is CCTCC (China Center For Type Culture Collection) NO: M 2025756. The bacillus cereus AK-LY1 disclosed by the invention is excellent in trypsin resistance, good in cholate resistance, acid resistance and high temperature resistance, good in inhibition performance on antibiotics such as strong penicillin and chloramphenicol, and relatively good in adhesion capacity in intestinal tracts, and provides a relatively good microecological preparation reference basis for expanding a bacillus cereus resource library and applying the bacillus cereus.

The invention relates to an exosome fusion liver targeting liposome drug delivery system as well as a preparation method and application thereof, and belongs to the field of high polymer material science and pharmaceutical preparations. The invention discloses an exosome-fused liver-targeted liposome drug delivery system, which combines high-concentration PEG8000 and Nycodenz in a breakthrough manner, synergistically improves the fusion efficiency of exosome and liposome, and forms bionic vesicles with uniform size and high drug loading capacity. The exosome not only can exert the anti-inflammatory and anti-oxidation characteristics, but also plays a role in resisting a severe gastrointestinal environment and crossing a biological barrier. In addition, liposome is modified by cholic acid derivatives through EDC / NHS mediated amidation reaction, precise targeting of the liver is achieved, and the liposome is fully accumulated in the liver. The effects synergistically realize the treatment of type II diabetes and non-alcoholic steatohepatitis.

The invention discloses a method for analyzing and identifying anti-inflammatory active ingredients of Xinhuang tablets based on a UPLC-Tripe-TOF-MS (Ultra Performance Liquid Chromatography-Tripe-TOF-Mass Spectrometry) spectrum-effect relationship. According to the method, an active extract is obtained from Xinhuang tablets through a dichloromethane liquid-liquid extraction method, a fingerprint spectrum of 10 batches of samples is established by using UPLC-Tripe-TOF-MS, a double-target evaluation system is constructed by combining an LPS-induced RAW264.7 cell inflammation model and COX-2 enzyme inhibition detection, and spectrum-effect relationship research is performed through gray correlation analysis and an OPLS-DA data mining technology. Four chemical components, namely indomethacin, 7-ketolithocholic acid, erucyl amide and pyranoapigenin, which are highly related to the anti-inflammatory activity are identified; the quality control method of the Xinhuang tablets based on the key chemical markers is established, a scientific basis is provided for quality evaluation and standardization of the traditional Chinese medicine compound Xinhuang tablets, and meanwhile a new thought is provided for development of anti-inflammatory drugs.

The invention provides a 7beta-hydroxysteroid dehydrogenase mutant and application thereof in synthesis of ursodesoxycholic acid by a biological enzyme method, through a genetic engineering technology and computer-aided design, phosphoric acid coordination residues of protein are modified, the 7beta-hydroxysteroid dehydrogenase (7beta-HSDH) mutant with higher activity under an NADH (Nicotinamide Adenine Dinucleotide Hydroxide) system is constructed, and the 7beta-hydroxysteroid dehydrogenase (7beta-HSDH) mutant can be used for synthesizing ursodesoxycholic acid. The modification strategy is suitable for other proteins for modifying cofactor preference and improving enzyme activity, and has remarkable industrial value when being used for efficiently catalyzing CDCA to be converted into UDCA through a one-pot one-step method.

A model that closely resembles human excessive myopia can be prepared by mounting a minus lens (2) and a protector (4) to a juvenile mouse, the minus lens having an angle and a width adjustable in response to growth of the mouse. Further, this model analysis shows that myopia induction causes endoplasmic reticulum stress in a sclera and the endoplasmic reticulum stress induces myopia. Furthermore, it is revealed that an endoplasmic reticulum stress suppressant, particularly, phenylbutyrate and tauroursodeoxycholic acid act as a myopia prevention / suppression agent.

Methods for stereo-selectively crystallizing 3-keto-5β-cholanic acid ("3-KCA") and 3-keto ursodeoxycholic acid ("3-KUDCA") of exceptional purity, salts useful in carrying out such methods, particularly the t-butylamine and cyclohexylamine salts of 3-KCA, the t-butylamine salt of 3-KUDCA, and crystalline forms of such salts, and methods of making commercial steroids from such purified materials.

The present disclosure relates to stable pharmaceutical compositions comprising fixed dose combination of obicetrapib and ezetimibe, or their salts, solvates or derivatives thereof. The disclosure further describes the use of ezetimibe and obicetrapib, e.g. in the form of such fixed dose combinations, for preparation of medicaments and method of treatment of subjects requiring reduction in LDL-cholesterol or those suffering from hyperlipidemia or mixed dyslipidemia.

The invention discloses a method for extracting bilirubin, cholic acid and chenodeoxycholic acid from chicken bile. The method comprises the steps of pretreatment, chicken bile treatment, hydrolysis reduction, chromatographic separation and the like. The method comprises the following steps: slicing frozen chicken gallbladder, heating, unfreezing and melting to denature protein into solid, then cooling, performing three-phase centrifugal degreasing and deproteinization, and adding three enzymes including biliverdin reductase, coenzyme I and glucose dehydrogenase to reduce free biliverdin and combined biliverdin, so as to obtain the biliverdin-free biliverdin-glucose dehydrogenase-free biliverdin-glucose dehydrogenase-free biliverdin-glucose dehydrogenase. The method comprises the following steps: adding cholic acid and chenodeoxycholic acid into a container, adding gluconic acid hydrolase and bile salt hydrolase to hydrolyze biliverdin and bile acid, adding trypsin to hydrolyze impure protein, performing chromatography by using macroporous silica gel, and separating bilirubin, cholic acid and chenodeoxycholic acid by using different molecular space structures to obtain high-purity bilirubin, cholic acid and chenodeoxycholic acid. The method has the advantages of simple process, few types of used solvents, low toxicity, and facilitation of environmental protection and industrial production.

The present invention discloses a synthesis method of ursodeoxycholic acid by using the plant-derived compound BA as a raw material to synthesize ursodeoxycholic acid through the steps of ethylene glycol or neopentyl glycol protection, oxidation, Wittig reaction, deprotection, reduction and hydrolysis, etc. The raw materials used for the synthesis of ursodeoxycholic acid in the present invention are cheap and easy to get, the synthesis steps are easy to operate, the yield is high, the reaction is environmentally friendly, and the industrial production is convenient.

The present invention relates to a composition for treatment of coronavirus disease 2019 (COVID-19) containing taurodeoxycholic acid (TDCA) or a pharmaceutically acceptable salt thereof as an active ingredient. Specifically, an early full recovery effect has been confirmed through the efficacy of treating clinical symptoms caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, alleviating inflammation, and inhibiting inflammatory cytokines using a pharmaceutically acceptable salt of taurodeoxycholic acid, and thus the taurodeoxycholic acid or a pharmaceutically acceptable salt thereof can be used as an active ingredient in a composition for prevention or treatment of lower respiratory tract infectious diseases, including coronavirus disease 2019.

The invention discloses a modified 7beta-hydroxysteroid dehydrogenase (7beta-HSDH), which has higher activity and stability in the synthesis process of ursodesoxycholic acid (UDCA), and takes NAD (P) H as a coenzyme. According to the 7beta-hydroxysteroid dehydrogenase mutant, the V104 site in the 7beta-hydroxysteroid dehydrogenase is subjected to saturated mutation modification, and the mutant with enhanced activity and changed coenzyme specificity is screened out. The mutant enzyme can keep high catalytic efficiency under the condition of taking NADH as a coenzyme, so that the synthesis yield of UDCA is remarkably increased, and the production cost is reduced. The enzyme mutant disclosed by the invention has a wide application prospect in industrial production, is particularly suitable for the production process of large-scale biosynthesis of UDCA, can effectively reduce the production cost, improve the product yield and reduce the environmental pollution and the production cost, and provides a technical support for wide application of UDCA.

The invention discloses lipid nanoparticles targeting liver cells as well as a preparation method and application of the lipid nanoparticles. Raw materials of the lipid nanoparticles comprise lipid targeting dirty cells, and the lipid targeting dirty cells is selected from at least one of galactosyl lipid, N-acetyl galactosamino lipid, lactosyl lipid, mannose-based lipid, glycolipid, glycerol glycolipid, steroid glycolipid, glycerol cholic acid lipid or N-alkenyl lipid. The low-toxicity lipid nanoparticle for efficiently targeting the liver is high in delivery efficiency, has remarkable liver targeting, low immunogenicity and excellent biocompatibility, and is applicable to delivery of various drugs, gene therapy and vaccines needing liver targeting delivery.

The invention discloses a biochemical immunodetection device and a biochemical immunodetection method for ursodesoxycholic acid reduzate, and belongs to the technical field of ursodesoxycholic acid reduzate detection. The ursodesoxycholic acid reduzate detection device comprises a detection box and a lifter at the bottom of the detection box, a dissolution preparation part and a centrifugal part are arranged in the detection box, and the dissolution preparation part can fully dissolve an ursodesoxycholic acid reduzate-containing medicament; the centrifugal part is used for carrying out precipitation separation on the dissolved medicament; the detector can accurately collect fluorescence signals of the immune complex; according to the ursodesoxycholic acid reduzate detection device, the integrated operation of detection test tube fixing, cover opening and transferring, medicament adding, cover closing and plug sealing and dissolving is achieved, the steps of automatic medicament filling, sealing and the like are achieved, the medicament preparation efficiency is greatly improved, efficient and accurate detection of ursodesoxycholic acid reduzate is further achieved, and the detection efficiency is improved. And complex and tedious manual operation is avoided, and the situation that the sample is easily polluted by manual operation is avoided.

The invention relates to the technical field of health wine preparation, and discloses a multi-effect synergistic enhanced bear gall body-building wine compound preparation process which comprises the following steps: taking sorghum, corn and fructus lycii as fermentation base materials, and carrying out double-strain synergistic fermentation by adopting saccharomyces cerevisiae and lactobacillus plantarum; adding fresh ursodesoxycholic acid during fermentation, carrying out in-situ enzymatic debinding conversion by using a compound enzyme system generated by a fermentation system, and converting the bound bile acid into free ursodesoxycholic acid; after fermentation, distilling to obtain raw wine; a molecularly imprinted polymer prepared by taking a wolfberry polyphenol key monomer as a template molecule is adopted to carry out targeted anchoring refining on raw wine, selective capture and enrichment of wolfberry polyphenol are carried out, and finally aging is carried out to obtain a finished product. According to the method disclosed by the invention, upstream double-strain fermentation in-situ enzymatic conversion and downstream molecular imprinting targeted refining are systematically integrated, so that the technical contradictions that the conversion rate of combined bile acid is low and a large amount of polyphenol functional components are synchronously lost during purification and impurity removal in a traditional process are solved.

The invention discloses a glycinin compound for preventing hyperlipemia as well as a preparation method and application of the glycinin compound, and belongs to the field of biological medicines. The preparation method comprises the following steps: stirring and mixing resveratrol and a soybean 7S globulin solution at 40-60 DEG C for 1.5-2.5 h, so that resveratrol and soybean 7S globulin are fully combined to obtain a glycinin compound; the mass ratio of the soybean 7S globulin to the resveratrol is (250: 50)-(250: 45). Experimental results show that the glycinin compound disclosed by the invention can inhibit the weight increase of a hyperlipemia rat, remarkably reduce the fat index and the liver index, effectively improve the abnormal change of the blood fat factor level and show an obvious lipid-lowering effect. In-vitro simulated digestion experiments show that the glycinin compound shows peptide fragments with different strength from soybean 7S protein after gastrointestinal digestion, and meanwhile, the glycinin compound improves the in-vitro cholate binding capacity.

The invention relates to the technical field of culture media, and particularly discloses a candida chromogenic culture medium as well as a preparation method and application thereof. The candida chromogenic culture medium disclosed by the invention is prepared from the following components in concentration: 10 to 11 g / L of peptone, 12 to 17 g / L of agar, 7 to 9 g / L of glucose, 1 to 2 g / L of chromogenic substrate and 0.4 to 0.6 g / L of bacteriostatic agent, the chromogenic substrate is formed by mixing heavy 4-nitrophenyl-N-acetyl-beta-D-galactosamine and 4-methylumbelliferone-beta-D-N-acetyl galactosamine, and the chromogenic substrate is formed by mixing heavy 4-nitrophenyl-N-acetyl-beta-D- The bacteriostatic agent is prepared by mixing chloramphenicol, taurocholic acid and nalidixic acid. When being used for detecting and identifying candida albicans, candida tropicalis, candida krusei and candida glabrata, the chromogenic culture medium provided by the invention has strong specificity, short identification time and wide practical application value.

The present invention discloses the application of 12-ketolithocholic acid in the preparation of anti-Veillonella products. The first test showed that 12-ketolithocholic acid has good activity in inhibiting atypical Veillonella. Specifically, by measuring the minimum inhibitory concentration required to inhibit 50% of the tested ATCC 17744 strain, the results showed that the bacteria in the blank control wells without drugs grew significantly, while the MIC50 of 12-ketolithocholic acid for atypical Veillonella was 294.7 μg / ml. Therefore, the new use of 12-ketolithocholic acid provided by the present invention provides a reference for the clinical prevention and control of epidemics caused by Veillonella.

This invention belongs to the field of diagnostic testing technology. Addressing the problem that existing gestational diabetes screening methods may miss the optimal time for early intervention, leading to the failure to promptly detect and manage some potentially hyperglycemic pregnant women, increasing the risk of adverse maternal and fetal outcomes, this invention proposes a plasma metabolic biomarker for the early diagnosis or prediction of gestational diabetes and its application. This plasma metabolic biomarker is at least one of L-lysine, propargylglycine, N6-acetyl-L-lysine, cyclic leucine, and glycine-deoxycholic acid. The five plasma metabolic biomarkers provided by this invention can be applied to the early diagnosis or prediction of gestational diabetes, and are of great significance for the prevention or treatment of gestational diabetes.

The application relates to the technical field of biological pharmacy, and discloses a method for preparing high-bionic bovine bezoar by using a 3D printing technology and application. The preparation raw material of the high-bionic bovine bezoar comprises the following components: fermented bovine bile, saturated calcium hydroxide, hydroxypropyl methyl cellulose, bilirubin, cholic acid, deoxycholic acid and taurine; wherein the fermented bovine bile is obtained by fermenting bovine bile by using escherichia coli. The high-bionic bovine bezoar prepared by using the preparation raw material to perform 3D printing can be comparable to natural bovine bezoar in terms of components, effects and appearance, the main pharmaceutical components can be adjusted according to actual requirements, the production cost of the bovine bezoar can be greatly reduced, and the demand of people for the bovine bezoar can be met.

The invention discloses an application of astaxanthin in preparation of a regulator for improving the gentisic acid level. On the basis of non-targeted metabonomics analysis, it is found for the first time that in the SAP pathogenesis process, the level of a flora metabolite, namely gentisic acid (GA), in intestinal contents is remarkably reduced, and in-vivo gentisic acid level can be remarkably callback through astaxanthin intervention. Further research proves that exogenous supplement of gentisic acid can effectively simulate the protection effect of astaxanthin, including improvement of pancreatic tissue pathological damage, reduction of serum lipase and amylase activity, and inhibition of systemic inflammatory response (down-regulation of IL-1beta, IL-6 and TNF-alpha and up-regulation of IL-10). The invention not only discloses a new mechanism that astaxanthin plays a therapeutic role through an'intestinal flora-metabolite 'axis, but also determines that gentisic acid is used as a novel drug target for treating SAP, and constructs a new method for screening drugs for treating SAP according to the novel drug target.

A curcumin nanococrystal composition including curcumin, a coformer, and a stabilizer. The coformer may include at least one of 3,5-dinitrobenzoicacid, gentisic acid, phloroglucinol, 4,4-bipyridine, tartaric acid, citric acid, and gallic acid. The curcumin nanococrystal composition has a particle size less than 10 nm, and the curcumin has a water-solubility between 5 mg / ml and 20 mg / ml.

The invention relates to the field of biological catalysis, and discloses a method and a device for generating ursodesoxycholic acid through continuous flow catalysis of chenodeoxycholic acid. Comprising the following steps: (1) in the presence of first immobilized cells, carrying out a first catalytic reaction on a reaction system containing chenodeoxycholic acid to obtain a first product, the first immobilized cells expressing 7 alpha-hydroxysteroid dehydrogenase and lactic dehydrogenase; the concentration of the chenodeoxycholic acid in the reaction system is 40 to 70 mM; (2) adjusting the pH value of the first product to 8-9, and then in the presence of a second immobilized cell, carrying out a second catalytic reaction on the first product after the pH value is adjusted to obtain ursodesoxycholic acid, and the second immobilized cell expresses 7 beta-hydroxysteroid dehydrogenase and glucose dehydrogenase. According to the method, the stable activity of a catalytic system is kept, efficient conversion of high-concentration CDCA is achieved, meanwhile, precipitation of 7-KLCA is thoroughly avoided, and the synthesis efficiency, the product purity and the process continuity of UDCA are remarkably improved.

The application belongs to the field of neuropharmacology and medicine, and particularly relates to application of taurine cholic acid in preparation of a drug for preventing or treating Alzheimer's disease. Through animal model experiment verification, the A beta lateral ventricle injection is used to prepare an AD mouse model, and after oral administration of TCA for 2 weeks, cognitive behavior and pathological indexes are significantly improved.

The invention relates to the field of biomarkers, and particularly provides a polycystic ovarian syndrome pregnancy outcome diagnosis marker and application thereof. According to the present invention, the endometrial targeting metabonomics research is adopted to screen the disease-related potential metabolic markers such as N-Acetylaspartic acid, Suberic acid and isoallolithocholic acid, and the three metabolites are subjected to quantitative detection so as to accurately predict the pregnancy outcome of the polycystic ovarian syndrome patient, such that the pregnancy outcome of the polycystic ovarian syndrome patient can be accurately predicted, and the prediction of the pregnancy outcome of the polycystic ovarian syndrome patient can be easily achieved, such that the disease-related potential metabolic markers such as N-Acetylaspartic acid, suberic acid and isoallolithocholic acid can be provided. A new path is provided for early intervention of the disease state to improve the pregnancy outcome, and a new drug target is provided for evaluation of the endometrial function of the polycystic ovarian syndrome.

This invention relates to the field of biomedical technology, specifically to the application of 6-ketolithocholic acid in the preparation of drugs that reduce fat deposition. The 6-ketolithocholic acid in this invention inhibits the accumulation of lipid droplets in adipocytes and suppresses gene expression in the PPARγ pathway involved in lipid synthesis, thereby achieving the function of reducing fat deposition. The structural formula of the 6-ketolithocholic acid is: [Insert structural formula here].